Article Text

PDF
Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks

Statistics from Altmetric.com

OpenUrlCrossRefPubMed

Q Is olanzapine more effective for treating neurocognitive deficits than risperidone or haloperidol in people with schizophrenia?

METHODS

Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:

Concealed.

Embedded ImageBlinding:

Double blind.

Embedded ImageFollow up period:

52 weeks.

Embedded ImageSetting:

39 sites, USA and Canada; July 1999 to September 2000.

Embedded ImagePatients:

414 people with schizophrenia or schizoaffective disorder (DSM-IV; mean age 39 years; 71% men). Exclusions: <18 or >55 years old; fewer than two positive items on the Positive and Negative Symptoms scale with a score ⩾4; score <18 on the Brief Psychiatric Rating Scale; non-English speaking; <2 years since first diagnosis, treatment or hospitalisation; neurological disorder; head injury; serious illness; untreated hypothyroidism or hyperthyroidism; agranulocytosis; pregnant or nursing; substance dependence; treatment with depot antipsychotics, reversible monoamine oxidase inhibitor, clozapine, …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.